. This expression of resistance, to the same group of drugs as seen in the MDR mutant, does not require prior selection with cytotoxic agents and has been termed intrinsic MDR (Gupta, 1988) . In this work, for the first time, we show that several analogs of amiloride can reverse intrinsic MDR without greatly affecting the acquired MDR. Amiloride is an inhibitor of Na+/H+ antiport. The activity of this ion transporter is elevated in drug resistant cell lines (Boscoboinik et al., 1990) . Analogs of amiloride vary greatly in the potency and specificity by which they inhibit this antiporter (Kleyman & Cragoe, 1988 (Keizer & Joenje, 1989; Boscoboinik et al., 1990) , it seemed possible that acidification of pH,, through inhibition of the Na+/H+ antiporter, could contribute to the sensitisation of drug resistant cell lines.
. This form of multidrug resistance (MDR) has been referred to as acquired resistance. In addition, it has recently been shown that certain wild type cells, particular those derived from rodents, can be made more sensitive to cytotoxic drugs by agents (e.g. verapamil) which reverse MDR (Gupta, 1988) . This expression of resistance, to the same group of drugs as seen in the MDR mutant, does not require prior selection with cytotoxic agents and has been termed intrinsic MDR (Gupta, 1988) . In this work, for the first time, we show that several analogs of amiloride can reverse intrinsic MDR without greatly affecting the acquired MDR. Amiloride is an inhibitor of Na+/H+ antiport. The activity of this ion transporter is elevated in drug resistant cell lines (Boscoboinik et al., 1990) . Analogs of amiloride vary greatly in the potency and specificity by which they inhibit this antiporter (Kleyman & Cragoe, 1988 (Keizer & Joenje, 1989; Boscoboinik et al., 1990) , it seemed possible that acidification of pH,, through inhibition of the Na+/H+ antiporter, could contribute to the sensitisation of drug resistant cell lines.
Materials
Amiloride analogs were synthesised for this study by previously described methods (Cragoe et al., 1967 Whitmore, 1974) . The Pro-and AUXBI cell lines show similar sensitivity towards various drugs used in the present study (Gupta, R.S., unpublished results). The cell line CHRC5 was derived from AUXBI after three successive selections in presence of increasing concentrations of colchicine (Ling & Thompson, 1974) . The CHRC5 cell line (Bech-Hansen et al., 1976) was kindly provided by Dr Victor Ling of the Ontario Cancer Institute, Toronto, Ontario. HeLa (clone S3) is a human cell line established from a cervical carcinoma (Puck et al., 1956 ). All of the above cell lines were grown as monolayer cultures in a-MEM + nucleosides supplemented with 5-10% foetal bovine serum at 37°C in a humidified incubator in an atmosphere of 95% air and 5% CO2. The cell lines were routinely grown in the absence of any selective drug without loss of resistance.
Clonogenic assay
The effect of various agents on the reversal of the drugresistance was examined by determining the cloning efficiencies of the parental and resistant cell lines in the presence of different concentrations of either vinblastine, daunomycin, puromycin or colchicine, in the absence and presence of the amiloride analogs. In these experiments, which were carried out in 24-well tissue culture dishes, 0.5 ml of 11 progressive dilutions of cytotoxic drug (made at two times the final concentrations in growth medium) were added to duplicate wells of 24-well dishes. These dilutions were chosen to cover a range of concentrations both above and below the cytotoxic level either in the presence or in the absence of sensitiser. Generally, 11 different concentrations of the drug, in addition to a control without any drug, were employed. The single cell suspensions of the cell lines were suitably diluted (based on cell count measurement done by Coulter counter), and 0.5 ml of these suspensions, containing 200 or 500 cells together with a fixed concentration of amiloride analog were then added to the wells of 24-well dishes. The experiments were carried out in parallel with and without the reversing agents. Amiloride analog solutions were made in dimethyl sulfoxide (DMSO); vinblastine sulfate solutions were made in ethanol and diluted in medium. The final concentration of solvent present in the wells did not exceed 2% and in most cases was below 0.2%. The control dishes (i.e. without reversing agent) received an equivalent 
Results
A number of analogs of amiloride were tested for their ability to reverse multidrug resistance in Chinese hamster ovary (CHO) cells. These amiloride analogs (Table I) have been previously characterised for their effects on ion transport (Kleyman & Cragoe, 1988; Cragoe and coworkers, unpublished results) . Of the many compounds tested, several had activity as sensitisers (Table II) . That is, concentrations of amiloride analogs which alone had minimal effect on the number of colonies formed, sensitised cells to the cytotoxic action of vinblastine. The number of colonies formed in the presence of cytotoxic drug plus amiloride analog was always compared with control wells which contained only the amiloride analog. In general, these compounds were more effective in reversing the intrinsic MDR characteristic of CHO cells than in reversing acquired resistance. Several of the compounds which specifically reversed intrinsic resistance to vinblastine, were tested against other cytotoxic agents (Table III) . As with vinblastine, intrinsic but not acquired resistance to these other cytotoxic drugs is reversed by the amiloride analogs. In addition, these sensitisers have no effect on HeLa cells (Table III) , a cell line which does not exhibit intrinsic MDR (Gupta, 1988) . This was also found when vinblastine was used as the cytotoxic agent (data not shown).
One of the causes for resistance to cytotoxic drugs is a decreased accumulation of cytotoxic agent. This could explain why wild type cells take up more adriamycin than do resistant cells (Figure 1) . Panel a shows an enhancement of drug uptake in both WT and CHRC5 cell lines in the presence of DMP or naphthamil. This is consistent with the partial reversal of both intrinsic and acquired resistance by these sensitisers (Table II) . However, the effects of phenamil, HPA and MIBA on adriamycin uptake (Figure 1, panel b) are specific for the WT cell line, with no increase in uptake seen with the resistant cell line. These three drugs were effective in reversing only intrinsic and not acquired resistance (Table II) . 
Discussion
The observation that some of the amiloride analogs are more effective against intrinsic MDR than acquired MDR is of particular interest. These are the only sensitisers that have been shown to affect intrinsic resistance more than acquired resistance. In contrast to these compounds, other agents such as verapamil, reserpine or cyclosporin concomitantly reverse both intrinsic as well as acquired MDR (Tsuruo et al., 1981; Twentyman et al., 1987; Gupta, 1988 and unpublished results). Not only are sensitisers generally common to both intrinsic and acquired resistance, but also the drugs to which the cells are resistant are the same.
The mechanism of acquired MDR has been studied more extensively. Cell lines with acquired MDR overexpress a 170 kDa membrane glycoprotein, the P-glycoprotein (van der Bliek et al., 1986; Fojo et al., 1987; Scheper et al., 1988; Juranka et al., 1989) . This P-glycoprotein is believed to function as an ATP-dependent efflux pump for cytotoxic drugs (Juranka et al., 1989) . However, it is not clear that this is the sole mechanism for acquired MDR and several discrepancies between the level of P-glycoprotein expression and the level of acquired resistance have appeared in the literature. In addition, little is known about the mechanism of sensitisation or reversal of acquired resistance. It has been suggested that sensitisers increase drug accumulation by competing with cytotoxic drugs for sites on the P-glycoprotein efflux pump (Horio et al., 1988) . However, one sensitiser, cyclosporin A, has been shown to reverse acquired MDR in some cell lines but not in DC3F/ADX cells, despite the fact that these cells overexpress P-glycoprotein (Boscoboinik et al., 1990) . The mechanism of intrinsic MDR is even less well understood. Based on very similar characteristics of intrinsic MDR and acquired MDR (with regard to drug cross resistance pattern and reversal by agents such as verapamil, reserpine, etc.), the mechanisms responsible for the two should be related. Therefore, differences in P-glycoprotein expression between human and rodent cells may be responsible for the intrinsic MDR phenotype of the latter cells. In this context, our observation that the intrinsic and acquired MDR phenotypes differ with regard to their reversal by amiloride analogs points to some subtle differences in the resistance mechanism. It should however, be mentioned that acquired MDR cell lines which overexpress P-glycoprotein are also known to differ in their reversal characteristics by cyclosporin A (Boscoboinik et al., 1990) . The different reversing agents may provide a valuable probe for examining the heterogeneity of the MDR phenotype and for investigating the underlying mechanism(s).
Although some of the drug sensitising amiloride analogs are potent inhibitors of Na+/H+ antiport, this does not seem to be their mechanism of action since some antiport inhibitors are not sensitisers and some sensitisers are not inhibitors. In addition, although three of the amiloride analogs which act as sensitisers are potent Na+ channel inhibitors, i.e. phenamil, HPA and DMP, this also does not account for the mechanism of action of all of the amiloride analogs. It is, of course, possible that different sensitisers function by different mechanisms. However, a simpler and more likely explanation is that this group of related compounds are among the several hydrophobic and cationic amphiphiles that reverse multidrug resistance and that their action is independent of inhibition of ion fluxes.
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